Assessing User Fees Under the Prescription Drug User Fee Amendments of 2022

[FDA]

This guidance provides information to stakeholders regarding EFDA’s implementation of the Prescription Drug User Fee Amendments of 2022 (PDUFA VII) under Title I of The FDA User Fee Reauthorization Act of 2022.


Baca selengkapnya di : http://www.fda.gov...